Is Clavulanic acid + Ticarcillin approved by the US FDA?

Drugs@FDA lists 3 application product lines for Clavulanic acid + Ticarcillin, including TIMENTIN (Discontinued); TIMENTIN (Discontinued); TIMENTIN IN PLASTIC CONTAINER (Discontinued).

Is Clavulanic acid + Ticarcillin authorised in the United Kingdom?

The MHRA category lists of UK marketing authorisations include 1 product containing Clavulanic acid + Ticarcillin, including TIMENTIN 0.8G, 1.6G, 3.2G.

Active substances

Clavulanic acid + Ticarcillin

US FDA 3
UK MHRA 1

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
TIMENTIN	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL; EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL; EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	injectable · injection	GLAXOSMITHKLINE	Discontinued	1 Apr 1985
TIMENTIN	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	injectable · injection	GLAXOSMITHKLINE	Discontinued	19 Dec 1986
TIMENTIN IN PLASTIC CONTAINER	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	injectable · injection	GLAXOSMITHKLINE	Discontinued	15 Dec 1989

UK MHRA United Kingdom — marketing authorisations

Product	Authorisation	Holder	Legal status
TIMENTIN 0.8G, 1.6G, 3.2G	PL 45352/0003	LABORATOIRES DELBERT	POM

Components

Clavulanic acid

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.